Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) shares reached a new 52-week high on Monday . The company traded as high as $48.41 and last traded at $46.19, with a volume of 298488 shares changing hands. The stock had previously closed at $46.01.
Gemini Therapeutics Stock Performance
The company has a market capitalization of $1.98 billion, a P/E ratio of -45.90 and a beta of -0.12. The firm’s fifty day moving average is $48.81 and its 200-day moving average is $42.23.
About Gemini Therapeutics
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Read More
- Five stocks we like better than Gemini Therapeutics
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- Best Stocks Under $10.00
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- How Can Investors Benefit From After-Hours Trading
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
